Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/TMEM214_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/TMEM214_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TMEM214_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TMEM214_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TMEM214_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TMEM214_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TMEM214 | SNV | Missense_Mutation | novel | c.713T>C | p.Leu238Pro | p.L238P | Q6NUQ4 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
TMEM214 | SNV | Missense_Mutation | novel | c.539N>A | p.Gly180Glu | p.G180E | Q6NUQ4 | protein_coding | deleterious(0.03) | benign(0.274) | TCGA-A2-A259-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
TMEM214 | SNV | Missense_Mutation | novel | c.520N>T | p.Val174Leu | p.V174L | Q6NUQ4 | protein_coding | tolerated(0.29) | benign(0.084) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
TMEM214 | SNV | Missense_Mutation | novel | c.739N>G | p.Ser247Ala | p.S247A | Q6NUQ4 | protein_coding | tolerated(0.06) | possibly_damaging(0.825) | TCGA-AN-A0FD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TMEM214 | SNV | Missense_Mutation | | c.1588N>A | p.Ala530Thr | p.A530T | Q6NUQ4 | protein_coding | tolerated(0.35) | benign(0.006) | TCGA-BH-A1FG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TMEM214 | SNV | Missense_Mutation | | c.1064G>C | p.Gly355Ala | p.G355A | Q6NUQ4 | protein_coding | deleterious(0.05) | benign(0.271) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TMEM214 | SNV | Missense_Mutation | rs368363508 | c.548N>A | p.Arg183Gln | p.R183Q | Q6NUQ4 | protein_coding | deleterious(0.04) | benign(0.012) | TCGA-D8-A27L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin+cuclophosphamide | SD |
TMEM214 | insertion | In_Frame_Ins | novel | c.715_716insCAGTGGGAGAAATGACCGCCACACACTCAACACTCACCA | p.Gly239delinsAlaValGlyGluMetThrAlaThrHisSerThrLeuThrSer | p.G239delinsAVGEMTATHSTLTS | Q6NUQ4 | protein_coding | | | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
TMEM214 | insertion | Frame_Shift_Ins | novel | c.1822_1823insCTCCCAGGGAGGGGAGAGGAGAGGCAGAAGAG | p.Gln608ProfsTer17 | p.Q608Pfs*17 | Q6NUQ4 | protein_coding | | | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TMEM214 | insertion | Frame_Shift_Ins | novel | c.337_338insCC | p.Glu113AlafsTer4 | p.E113Afs*4 | Q6NUQ4 | protein_coding | | | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |